

Cleo Diagnostics Limited  
Appendix 4D  
Half-year report

1. Company details

Name of entity:	Cleo Diagnostics Limited
ABN:	13 655 717 169
Reporting period:	For the half-year ended 31 December 2024
Previous period:	For the half-year ended 31 December 2023

2. Results for announcement to the market

			\$
Revenues from ordinary activities	Down	3.4% to	190,795
Loss from ordinary activities after tax attributable to the owners of Cleo Diagnostics Limited	Down	25.31% to	(1,950,364)
Loss for the half-year attributable to the owners of Cleo Diagnostics Limited	Down	25.31% to	(1,950,364)

Dividends

No dividend has been paid or declared by the company during the period.

Comments

The loss for the company amounted to \$1,950,364 (31 December 2023: \$2,611,241).

The company has commenced clinical trials in the US and in Australia, and is progressing its application to have the licenced technology patented throughout the various global jurisdictions. Details of activities are contained in the Review of operations, included in the 31 December 2024 Half Year Report.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	5.49	6.99

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

7. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

8. Attachments

*Details of attachments (if any):*

The Interim Report of Cleo Diagnostics Limited for the half-year ended 31 December 2024 is attached.

9. Signed



Signed \_\_\_\_\_

Date: 27 February 2025

Adrien Wing  
Director  
Melbourne

For personal use only

# Cleo Diagnostics Limited

ABN 13 655 717 169

## Half-Year Report – 31 December 2024

For personal use only



Review of Operations	3
Directors' Report	4
Auditor's Independence Declaration	6
Statement of Profit or Loss and Other Comprehensive Income	7
Statement of Financial Position	8
Statement of Changes In Equity	9
Statement of Cash Flows	10
Notes to the Financial Statements	11
Directors' Declaration	15
Independent Auditor's Report to the Members of Cleo Diagnostics Limited	16
Corporate Directory	18

For personal use only

Cleo Diagnostics Limited (**ASX:COV**) (**CLEO**, or the **Company**) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker. CLEO's test is designed to distinguish benign from malignant growths and will be compatible with standard diagnostic laboratory workflows worldwide.

CLEO is advancing the availability of its simple blood test, under a modular execution strategy to ultimately address all ovarian cancer detection markets with specific tests for surgical triage, recurrence, high risk, and early-stage screening.

During the half-year ending 31 December 2024, and up to the date of this report, CLEO has already delivered and made material progress against its strategy to make accurate and earlier detection of ovarian cancer a reality. Highlights include:

## Commercial

- FDA-enabling U.S. clinical trials commenced with:
  - Patient recruitment targeting a minimum of 500 patients, including diversity representative of the U.S. population;
  - Initial medical trial locations established and active.
  - All onboarding and activation initiatives associated with the U.S. medical recruitment centres completed;
  - The Company is now transitioning to broaden the number and scope of participating medical centres and ramp up patient recruitment to ensure collection milestones are met. An additional 6 sites are currently being considered to join the 7 current operational trial sites; and
  - Patient recruitment is ongoing with the trials designed to validate the use of CLEO's ovarian cancer diagnostic blood test for the U.S. market.

Initial pre-submission meetings held with the U.S. Food & Drug Administration (**FDA**) where CLEO outlined its submission framework and clinical plan;

CLEO remains on track for submission to FDA by end of CY2025;

Supporting Australian trials expanded with the inclusion of:

- Siles Health - network of 13 clinics across Melbourne and regional Victoria also joined the trial. Siles Health is a prominent women's health and ultrasound specialist, with Associate Professor Charles Siles, acting as Principal Investigator; and
- The Royal Women's Hospital Melbourne - with eminent gynaecological oncology specialist, Associate Professor Orla McNally, acting as Principal Investigator. The Women's is Australia's leading specialist hospital for women's health.

CLEO continues to strategically develop and broaden its capabilities for pre-launch physician engagement, development of strategic educational materials and broader stakeholder engagement. CLEO's medical affairs strategy is being developed in collaboration with U.S.-based Dr Karla Loken DO FACOOG. Dr Loken has extensive expertise in medical affairs with specific expertise in the medical device area.

## Manufacturing

- Internationally-based commercial test-kit manufacturer appointment is in final stages;
- Appointment will initially focus on completion of alpha prototype testing; and
- A binding agreement to follow including commencement of technology transfer.

## Technology Development

- CLEO has commenced negotiations with a potential manufacturer relating to technology transfer activities to support future manufacturing activities, specifically antibody production. Antibodies produced from these will form a key part of the pre-surgical triage test biomarker panel.

## Financial

- The Company ended the period with \$7.311M cash at bank; and
- CLEO is operating in line with its budgeted plan as outlined in the Company's prospectus, and continues to be appropriately funded to execute on its strategic plan.

## Corporate

- Management capacity enhanced with three key appointments:
  - Mr Nathan Hodgson as Head of Operations. Mr Hodgson was most recently engaged with Merck Germany, and he will bring a wealth of experience to CLEO managing contract manufacturing relationships and supply chain requirements; and
  - Ms Emma Lester as Quality & Regulatory Manager. Ms Lester is an accomplished quality and regulatory professional with over 15 years of experience in quality management, specialising in laboratory developed tests

and medical devices. She has experience in securing 510(k) approval and is known for her meticulous attention to detail and pragmatic approach to meeting business objectives and driving efficiency. Emma holds a Bachelor of Forensic Science (Biology) and Bachelor of Criminology from Griffith University; and

- Ms Dayna Louca as Head of Corporate Development. Ms Louca has over 11 years' experience primarily working at Deloitte with a focus on life sciences, across corporate development, equity research, and M&A. She has also advised ASX listed companies with respect to marketing, investor engagement, and capital markets. Dayna is a Chartered Accountant, and holds a Bachelor of Commerce (Dual Major in Accounting and Finance) from the University of Queensland.

The Company held its Annual General Meeting of shareholders on 27 November 2024 at 10.30am (AEDT). All resolutions considered at the Annual General Meeting were put to a vote on a Poll, called by the Chairman, and were passed. The directors submit herewith the interim Financial Report on Cleo Diagnostics Limited (referred to hereafter as the 'company') for the half-year ended 31 December 2024.

## Directors

The following persons were directors of Cleo Diagnostics Limited during the whole of the financial period and up to the date of this report, unless otherwise stated:

A M Wing  
R Allman  
A N Stephens  
L Nolan  
T W Jobling

## Principal activities

Cleo's principal activities involve the development and patent of a blood test for the detection of ovarian cancer, with the potential to substantially improve the existing standard of care. During the period the company's focus was on securing patents throughout global jurisdictions for the testing technology licenced from Hudson Institute of Research ("Hudson"), and the commencement of clinical trials in the United States and Australia.

## Review of operations

The loss for the company after providing for income tax amounted to \$1,950,364 (31 December 2023: \$2,611,241). This included Research and Development expenditure of \$1,362,574 (2023: \$1,843,877) and employee benefits cost of \$526,776 (2023: \$396,444). The 2023 loss was impacted by the payment of the first milestone payment under the licence agreement with Hudson, amounting to \$1,500,000 paid in ordinary shares issued to Hudson.

The Company has net assets at 31 December 2024 of \$7,441,668 (30 June 2024: \$9,392,032), including net current assets of \$7,029,886 (30 June 2024: \$8,951,753). Cash and cash equivalents at 31 December 2024 was \$7,310,872 (30 June 2024: \$9,372,963).

## Significant changes in the state of affairs

There were no other significant changes in the state of affairs of the company during the period.

## Events after reporting date

No matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

## Rounding of amounts

The company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

## Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 6.

**Cleo Diagnostics Limited**  
**Directors' Report**  
**31 December 2024**

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors



---

Adrien Wing  
Director

27 February 2025  
Melbourne

For personal use only

**RSM Australia Partners**

Level 27, 120 Collins Street Melbourne VIC 3000

PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000

F +61 (0) 3 9286 8199

[www.rsm.com.au](http://www.rsm.com.au)**AUDITOR'S INDEPENDENCE DECLARATION**

As lead auditor for the review of the financial report of Cleo Diagnostics Ltd for the half year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.

A stylized blue ink signature of "RSM".**RSM AUSTRALIA PARTNERS**A blue ink signature of "J S Croall".

**J S CROALL**  
Partner

Date: 27 February 2025  
Melbourne, Victoria



	Note	2024 \$	2023 \$
<b>Other income</b>	2	190,795	197,534
<b>Expenses</b>			
Administration wages and salaries		(526,776)	(396,444)
Professional fees		(50,537)	(99,455)
Compliance costs		(68,317)	(236,373)
Investor relations		(46,591)	(76,627)
Research and development expenditure	3	(1,362,574)	(1,843,877)
Depreciation and amortisation		(29,890)	(29,483)
Finance expense		-	(26,516)
Other expenses		(56,474)	(100,000)
<b>Loss before income tax expense</b>		(1,950,364)	(2,611,241)
Income tax expense		-	-
<b>Loss after income tax expense for the year attributable to the company</b>		(1,950,364)	(2,611,241)
<b>Other comprehensive income</b>			
Other comprehensive income for the year, net of tax		-	-
<b>Total comprehensive loss for the year attributable to the company</b>		<u>(1,950,364)</u>	<u>(2,611,241)</u>
		<b>\$</b>	<b>\$</b>
<b>Loss per share from continuing operations attributable to the owners of Cleo Diagnostics Limited</b>			
Basic loss per share		(0.017)	(0.02)
Diluted loss per share		(0.017)	(0.02)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

	Note	31 December 2024 \$	30 June 2024 \$
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		7,310,872	9,372,763
Trade and other receivables		82,620	57,444
Prepayments		84,294	7,762
Total current assets		<u>7,477,786</u>	<u>9,437,969</u>
<b>Non-current assets</b>			
Intangible assets	4	383,333	408,333
Property plant and equipment		<u>28,449</u>	<u>31,946</u>
Total non-current assets		<u>411,782</u>	<u>440,279</u>
<b>Total assets</b>		<u><u>7,889,568</u></u>	<u><u>9,878,248</u></u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		389,651	439,863
Employee benefits		<u>58,249</u>	<u>46,353</u>
Total current liabilities		<u>447,900</u>	<u>486,216</u>
<b>Total liabilities</b>		<u>447,900</u>	<u>486,216</u>
<b>Net assets / (liabilities),</b>		<u><u>7,441,668</u></u>	<u><u>9,392,032</u></u>
<b>Equity</b>			
Issued capital	5	13,706,586	13,706,586
Reserves	6	1,218,111	1,218,111
Accumulated losses		<u>(7,483,029)</u>	<u>(5,532,665)</u>
<b>Total equity</b>		<u><u>7,441,668</u></u>	<u><u>9,392,032</u></u>

The above statement of financial position should be read in conjunction with the accompanying notes

**Cleo Diagnostics Limited**  
**Statement of Changes in Equity**  
**For the period ended 31 December 2024**



	Issued capital	Reserves	Accumulated losses	Total equity
	\$	\$	\$	\$
Balance at 1 July 2023	46,531	783,485	(1,773,431)	(943,415)
Loss after income tax expense for the period	-	-	(2,611,241)	(2,611,241)
Other comprehensive income for the period, net of tax	-	-	-	-
Total comprehensive loss for the period	-	-	(2,611,241)	(2,611,241)
Transactions with owners in their capacity as owners:				
Issue of shares	12,000,000	-	-	12,000,000
Conversion of convertible notes	1,600,000	-	-	1,600,000
Capital raising costs	(1,439,945)	434,626	-	(1,005,319)
Share based payments – IP licence	1,500,000	-	-	1,500,000
Balance at 31 December 2023	13,706,586	1,218,111	(4,384,672)	10,540,025
	Issued capital	Reserve	Accumulated losses	Total equity
	\$	\$	\$	\$
Balance at 1 July 2024	13,706,586	1,218,111	(5,532,665)	9,392,032
Loss after income tax expense for the period	-	-	(1,950,364)	(1,950,364)
Other comprehensive income for the period, net of tax	-	-	-	-
Total comprehensive loss for the year			(1,950,364)	(1,950,364)
Transactions with owners in their capacity as owners:				
Balance at 31 December 2024	13,706,586	1,218,111	(7,483,029)	7,441,668

The above statement of changes in equity should be read in conjunction with the accompanying notes

	Note	2024 \$	2023 \$
<b>Cash flows from operating activities</b>			
Payments to suppliers and employees (inclusive of GST)		(2,212,040)	(1,338,978)
Interest received		151,541	43,004
Net cash used in operating activities		<u>(2,060,499)</u>	<u>(1,295,974)</u>
<b>Cash flows from investing activities</b>			
Payments for property plant and equipment		<u>(1,392)</u>	<u>(1,876)</u>
Net cash used in investing activities		<u>(1,392)</u>	<u>(1,876)</u>
<b>Cash flows from financing activities</b>			
Proceeds from issue of shares		-	12,000,000
Payment of listing fees		-	(834,287)
Net cash from financing activities		<u>-</u>	<u>11,165,713</u>
Net increase in cash and cash equivalents		(2,061,891)	9,867,863
Cash and cash equivalents at the beginning of the financial year		<u>9,372,763</u>	<u>239,774</u>
Cash and cash equivalents at the end of the financial year		<u><u>7,310,872</u></u>	<u><u>10,107,637</u></u>

*The above statement of cash flows should be read in conjunction with the accompanying notes*

## **Note 1. Material accounting policy information**

These general purpose financial statements for the interim half-year reporting period ended 31 December 2024 have been prepared in accordance with Australian Accounting Standard AASB 134 '*Interim Financial Reporting*' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 '*Interim Financial Reporting*'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2024 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

### **Rounding of amounts**

The company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

### **Comparatives**

Where necessary comparative figures have been reallocated to ensure that all categories of expense are comparable year on year.

### **New or amended Accounting Standards and Interpretations adopted**

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting year.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

## **Note 2. Other income**

	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$'000</b>	<b>\$'000</b>
Interest receivable – bank deposits	190,795	171,018
Interest receivable – convertible notes	-	26,516
	<u>190,795</u>	<u>197,534</u>

### **Accounting policy**

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

## **Note 3. Items included in expenses**

	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Research and development expenditure	<u>1,362,574</u>	<u>1,843,877</u>

Included in the prior year expense is \$1,500,000 paid via the issue of shares upon completion of the IPO pursuant to the licencing agreement with Hudson Institute of Medical Research (see note 4).

**Note 4. Non-current assets – intangible assets**

	31 December 2024 \$	30 June 2024 \$
Licence acquired	500,000	500,000
Licence – accumulated amortisation	<u>(116,667)</u>	<u>(91,667)</u>
	<u>383,333</u>	<u>408,333</u>

The company entered into a licence agreement with Hudson Institute of Medical Research that was signed on 29 August 2022.

The licence agreement gave the company exclusive rights to commercialise the licenced technology. In the period ended 30 June 2022 the company had paid a deposit pursuant to the licence agreement, paying the remaining \$300,000 upon signing of the agreement. The agreement also provided for the company to issue shares to the value of \$1,500,000 and 7,500,000 ordinary shares were issued on the lodgement of a prospectus to list the company. A further payment of \$1,500,000 in cash is provided in the agreement upon achievement of the first regulatory approval for the first product in the USA (FDA), Australia (TGA), Europe (CE) or Japan (PMDA). The agreement also included a royalty of 3% on net sales, plus levies on any sub-licensing agreements entered into by the company.

**Note 5. Equity - issued capital**

	31 December 2024 No.	\$	30 June 2024 No.	\$
Ordinary shares - fully paid	<u>128,500,001</u>	<u>13,706,586</u>	<u>128,500,001</u>	<u>13,706,586</u>

*Ordinary shares*

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

*Escrow*

At 31 December 2024 46,900,000 ordinary shares were escrowed until 22 August 2025.

**Note 6. Equity – reserves**

	31 December 2024 \$	30 June 2024 \$
Share based payments reserve	<u>1,218,111</u>	<u>1,218,111</u>
	<u>1,218,111</u>	<u>1,218,111</u>

*Purpose of reserve*

The reserve is used to record the value of equity instruments issued to employees, directors and service providers as part of their remuneration, and other parties as part of compensation for their services.

**Note 7. Equity – dividends**

No dividends were paid during the financial year.

**Note 8. Contingent assets**

The company had no contingent assets at 31 December 2024 (30 June 2024: Nil).

**Note 9. Contingent liabilities**

Under the licence agreement the company is required to pay to Hudson:

- the sum of \$1.5 million upon the achievement of the first regulatory milestone, being the first regulatory approval achieved by the company.

**Note 10. Commitments**

At 31 December 2024 the Company has no commitments.

For personal use only

#### **Note 11. Operating segments**

The company has adopted AASB 8 Operating Segments whereby segment information is presented using a “management approach”. Management has determined the operating segments based on the reports reviewed by the Chief Operating Decision Makers, in the company’s case being the Board of Directors, that are used to make strategic decisions. At 31 December 2024 the company operates predominately in Australia, and is carrying out trials in the United States. However, the company does not have any operating segments with discrete financial information as all operations are currently managed directly by management from Australia. The company does not have any customers outside Australia, and all the company’s assets and liabilities are located within Australia.

The Board of Directors review internal management reports at regular intervals that are consistent with the information provided in the Statement of Profit or Loss and Other Comprehensive Income, Statement of Financial Position and Statement of Cash Flows. As a result, no reconciliation is required because the information as presented is what is used by the Board of Directors to make strategic decisions including assessing performance and in determining the allocation of resources.

#### **Note 12. Events after the reporting period**

No matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

For personal use only



In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the company's financial position as at 31 December 2024 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors



---

Adrien Wing  
Director

27 February 2025  
Melbourne

For personal use only

**RSM Australia Partners**

Level 27, 120 Collins Street Melbourne VIC 3000  
PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000

F +61 (0) 3 9286 8199

[www.rsm.com.au](http://www.rsm.com.au)

## INDEPENDENT AUDITOR'S REVIEW REPORT

To the Members of Cleo Diagnostics Limited

### Report on the Half-Year Financial Report

#### Conclusion

We have reviewed the accompanying half-year financial report of Cleo Diagnostics Limited which comprises the statement of financial position as at 31 December 2024, the statement of profit and loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Cleo Diagnostics Limited is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the company's financial position as at 31 December 2024 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.

#### Basis for Conclusion

We conducted our review in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Cleo Diagnostics Limited, would be in the same terms if given to the directors as at the time of this auditor's report.

#### *Directors' Responsibility for the Half-Year Financial Report*

The directors of Cleo Diagnostics Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.


#### *Auditor's Responsibility for the Review of the Financial Report*

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the company's financial position as at 31 December 2024 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



**RSM AUSTRALIA PARTNERS**



**J S CROALL**

Partner

Dated: 27 February 2025

Melbourne, Victoria

For personal use only

Directors	Adrien Wing Richard Allman Andrew Stephens Lucinda Nolan Thomas Jobling
Company secretary	Pauline Moffatt
Registered office	Level 2 480 Collins Street Melbourne VIC 3000
Principal place of business	Level 2 480 Collins Street Melbourne VIC 3000
Share register	Xcend Pty Ltd Level 2, 145 William Street Darlinghurst NSW 2010
Auditor	RSM Australia Partners Level 27, 120 Collins Street Melbourne Vic 3000
Solicitors	Hamilton Locke Level 48, 152-158 St Georges Terrace Perth WA 6000
Bankers	National Australia Bank Level 29, 395 Bourke Street Melbourne Vic 3000
Stock exchange listing	Cleo Diagnostics Limited shares are listed on the Australian Securities Exchange (ASX:COV)
Website	<a href="http://www.cleodx.com">www.cleodx.com</a>
Corporate Governance Statement	<a href="https://cleodx.com/about/corporate-governance/">https://cleodx.com/about/corporate-governance/</a>

For personal use only

Cleo Diagnostics Limited  
Appendix 4D  
Half-year report

1. Company details

Name of entity:	Cleo Diagnostics Limited
ABN:	13 655 717 169
Reporting period:	For the half-year ended 31 December 2024
Previous period:	For the half-year ended 31 December 2023

2. Results for announcement to the market

			\$
Revenues from ordinary activities	Down	3.4% to	190,795
Loss from ordinary activities after tax attributable to the owners of Cleo Diagnostics Limited	Down	25.31% to	(1,950,364)
Loss for the half-year attributable to the owners of Cleo Diagnostics Limited	Down	25.31% to	(1,950,364)

Dividends

No dividend has been paid or declared by the company during the period.

Comments

The loss for the company amounted to \$1,950,364 (31 December 2023: \$2,611,241).

The company has commenced clinical trials in the US and in Australia, and is progressing its application to have the licenced technology patented throughout the various global jurisdictions. Details of activities are contained in the Review of operations, included in the 31 December 2024 Half Year Report.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	5.49	6.99

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

7. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

8. Attachments

*Details of attachments (if any):*

The Interim Report of Cleo Diagnostics Limited for the half-year ended 31 December 2024 is attached.

9. Signed



Signed \_\_\_\_\_

Date: 27 February 2025

Adrien Wing  
Director  
Melbourne

For personal use only